MMP16 and cancer: Degradation of miR-216a-5p targets is the dominant effect of miR-216a-5p in cancer, including (i) inhibition of hexokinase-2 in uveal melanoma [28] and (ii) down-regulation of matrix metalloproteinase 16 in lung cancer [15].